485 related articles for article (PubMed ID: 16847145)
21. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
22. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
24. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
25. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
26. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Rochdi M; Howell SB
Mol Pharmacol; 2003 Aug; 64(2):466-73. PubMed ID: 12869652
[TBL] [Abstract][Full Text] [Related]
27. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
[TBL] [Abstract][Full Text] [Related]
28. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
29. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.
Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U
Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621
[TBL] [Abstract][Full Text] [Related]
30. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
31. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
32. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
33. [Structure-functional organization of eukaryotic high-affinity copper importer CTR1 determines its ability to transport copper, silver and cisplatin].
Skvortsov AN; Zatulovskiĭ EA; Puchkova LV
Mol Biol (Mosk); 2012; 46(2):335-47. PubMed ID: 22670529
[TBL] [Abstract][Full Text] [Related]
34. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
35. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.
Shen DW; Goldenberg S; Pastan I; Gottesman MM
J Cell Physiol; 2000 Apr; 183(1):108-16. PubMed ID: 10699972
[TBL] [Abstract][Full Text] [Related]
36. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
37. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
38. Transport of cisplatin by the copper efflux transporter ATP7B.
Safaei R; Otani S; Larson BJ; Rasmussen ML; Howell SB
Mol Pharmacol; 2008 Feb; 73(2):461-8. PubMed ID: 17978167
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma grown as multicellular spheroids.
Schwachöfer JH; Crooijmans RP; Hoogenhout J; Kal HB; Theeuwes AG
Anticancer Res; 1990; 10(3):805-11. PubMed ID: 2195988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]